Format
Sort by

Send to:

Choose Destination

Results: 5

1.

Osteopontin is a prognostic biomarker in non-small cell lung cancer.

Rud AK, Boye K, Oijordsbakken M, Lund-Iversen M, Halvorsen AR, Solberg SK, Berge G, Helland A, Brustugun OT, Mælandsmo GM.

BMC Cancer. 2013 Nov 11;13:540. doi: 10.1186/1471-2407-13-540.

2.

Clinical significance of disseminated tumour cells in non-small cell lung cancer.

Rud AK, Borgen E, Mælandsmo GM, Flatmark K, Le H, Josefsen D, Solvoll I, Schirmer CB, Helland Å, Jørgensen L, Brustugun OT, Fodstad Ø, Boye K.

Br J Cancer. 2013 Sep 3;109(5):1264-70. doi: 10.1038/bjc.2013.450. Epub 2013 Aug 13.

3.

Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer.

Rud AK, Lund-Iversen M, Berge G, Brustugun OT, Solberg SK, Mælandsmo GM, Boye K.

BMC Cancer. 2012 Aug 1;12:333.

4.

EGFR gene alterations in a Norwegian cohort of lung cancer patients selected for surgery.

Helland Å, Skaug HM, Kleinberg L, Iversen ML, Rud AK, Fleischer T, Sagerup C, Solberg S, Jørgensen L, Ariansen S, Brustugun OT.

J Thorac Oncol. 2011 May;6(5):947-50. doi: 10.1097/JTO.0b013e31820db209.

PMID:
21623266
5.

Hyperbaric oxygen therapy for late radiation tissue injury in gynaecological patients.

Rud AK, Bjørgo S, Kristensen GB, Kongsgaard UE.

Support Care Cancer. 2009 Dec;17(12):1517-21. doi: 10.1007/s00520-009-0619-1. Epub 2009 Mar 25.

PMID:
19319575
Format
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk